Quality Of Medicines in South Africa: Perceptions Vs. Reality A Patel 1,3 R Gauld 2 P Norris 3 T Rades 3 1 = Health Research for Action (HERA) 2 = Social.

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
Industry Analysis. Introduction Industry analysis takes two broad forms  Porter’s Five Forces Analysis  Brandenberger and Nalebuff’s Value Net Outcome.
Peter Carter Chief Executive Officer International Society for Quality in Health Care Physician Heal Thyself.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Pharmaceutical Services Unit Essential Medicines Management
Methods for measuring perceived qualities in the landscape - from quantitative to qualitative research Project B: Socio-cultural effects Sofia Jönsson,
Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:
WHO Guideline on Country Pharmaceutical Pricing Policies 1 |1 | ESSENTIAL MEDICINES AND HEALTH PRODUCTS WHO Guideline on Country Pharmaceutical Pricing.
Wellbeing for children and young people with a disability in New Zealand: A conceptual framework Counting Children In! Child Indicators: Research, Theory,
National Medicine Policy
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Pharmaceutical Manufacturers Association PMA Status of National Production Capacity of Generic Medicines – Private Sector Perspective Emmanuel Mujuru,
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Are we there yet? 15 Years of Introducing Emergency Contraception Elizabeth Westley, ICEC Coordinator Reproductive Health Supplies Coalition Membership.
Medicines Transparency Alliance10/10/2015 Updates on Quality Presentations et al. John Allotey Manager, Business Developments LaGray Chemical Company Limited.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Country Assessment to Determine Factors Influencing the Cost, Availability and Distribution of Acyclovir in Eight Sub-Saharan African Countries Catherine.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
4 th - 18 November 2011 ICIUM 2011 Conference Antalya, Turkey 16/10/2015.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
ACCESS TO MEDICINES - POLICY AND ISSUES
MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Identify a Health Problem Qualitative Quantitative Develop Program -theory -objectives -format -content Determine Evaluation -design -sampling -measures.
Development and Implementation of Good Pharmacy Practice Standards in Developing Countries Author: Frokjaer B, International Pharmaceutical Federation.
Pharmacists Perceptions of the Development of Herbal Medicines in Iran
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
1 CLUSTER : Pharmaceutical Policy & Planning Strategic Plans 2004/ /6 2006/7 31 May 2004.
Trade & Access to Medicines in India Centre for Trade & Development
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Overview and Rationale for Project Carlos Toledo, PhD Chief, HIV Prevention Branch Centers for Disease Control and Prevention (CDC)-South Africa.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
RECENT ADVANCES IN PROVISION OF PRIMARY HEALTH CARE BY MISSION ORGANIZATIONS THE EFFECT OF AN EDUCATIONAL INTERVENTION ON USE OF ANTIBIOTICS IN THE TREATMENT.
Rethinking Health Innovation from the South WORKSHOP South Africa/ Cape town December 13 – 15 /2010.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
Primary health care Dr. Hassan M. Alnuaimy Msc. Orthodontics.
Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Efficacy and Safety of Medicines
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
Implementing quality systems
Pharmacy Practices Provided by Dispensing Doctors in Zimbabwe
THE SELF MEDICATION MANUFACTURERS ASSOCIATION OF SOUTH AFRICA (SMASA)
Controlling Measuring Quality of Patient Care
HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.
Regulation of Medical Products & Patient Safety- A Narrative Review
Overview of the Office of Health Standards Compliance
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Overview of the Office of Health Standards Compliance
Purpose & Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Standardization on Medical Devices
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.
‘Data ethics and bio-banking’
Presentation transcript:

Quality Of Medicines in South Africa: Perceptions Vs. Reality A Patel 1,3 R Gauld 2 P Norris 3 T Rades 3 1 = Health Research for Action (HERA) 2 = Social and Preventive Medicine, University of Otago, New Zealand 3 = School of Pharmacy, University of Otago, New Zealand

INTRODUCTION WHO Defn: Essential Medicine available, affordable, safe, effective, quality- assured, information - outcomes. Quality: manufacture, registration, distribution, and pharmacovigilance. Access to affordable medicines: generic medicines policies.

South Africa NMP Generic Medicines Policy Pricing Regulations Regulatory Authority: MCC

AIM To compare the actual Quality of Selected Medicines to peoples’ understanding of medicine quality

Design Qualitative: Focus Groups (n=12) & key informant interviews (n=25) Purposive sampling of providers (n=25) & consumers (n= 73) Quantitative assessment of medicines: identity (FTIR), dissolution and uniformity of weight: BP Medicines: hydrochlorothiazide, amoxycillin and paracetamol (n= 135) Settings: Johannesburg, Cape Town and Durban

FINDINGS IN-vitro TESTRESULTS IDENTITY100% passed DISSOLUTION100% passed WEIGHT87% passed

QUALITY: PERCEPTIONS PROVIDERS’ & CONSUMERS’ VIEWS 1 QUALITY – “MEASURED” ON EFFECT PRODUCED “FREE”, STATE MEDICINES – “This body does not want mahala medicines” - SUSPICION GENERICS – MANUFACTURER NAME “REPUTATION”, SUPPLIER COUNTRY SELECTION – DEPENDENT ON PROVIDER (Dr preferred) 1 A Patel, R Gauld, P Norris, T Rades (2010) “This body does not want free medicines”: South African consumer perceptions of drug quality. Health Policy and Planning, 25 (1):

DISCUSSION In-vitro tests – positive results Providers – supplier origin & reputation; willingness to accept Consumers – depend on provider for information; confuse quality of care with quality of medicines

LESSONS PHARMACOLOGICAL THEORY – QUALITY & USE – BIOMEDICAL FRAMEWORK PEOPLE: SOCIAL & CULTURAL FRAMEWORKS GENERIC MANUFACTURERS – PROVIDERS OF INFORMATION

RECOMMENDATIONS REGULATOR: PRO-ACTIVELY MANAGE COMPLAINTS NMP IMPLEMENTATION: BIOMEDICAL AND THE SOCIO-CULTURAL WORLDS GENERIC SUBSTITUTION: MANAGE DEMAND

THANK YOU Poster 210.